pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia

Emerg Infect Dis. 2017 Mar;23(3):491-495. doi: 10.3201/eid2303.161034.

Abstract

Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polymorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drug-resistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drug-resistant tuberculosis.

Keywords: Georgia; South Africa; bacteria; drug resistance; pyrazinamide; sequencing; tuberculosis; tuberculosis and other mycobacteria.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Amidohydrolases / genetics
  • Amidohydrolases / metabolism*
  • Antitubercular Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Extensively Drug-Resistant Tuberculosis / epidemiology*
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Georgia (Republic) / epidemiology
  • Humans
  • Mutation
  • Pyrazinamide / pharmacology*
  • South Africa / epidemiology

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Amidohydrolases
  • PncA protein, Mycobacterium tuberculosis